Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

[HTML][HTML] SARS-CoV-2 Omicron variant: recent progress and future perspectives

Y Fan, X Li, L Zhang, S Wan, L Zhang… - Signal transduction and …, 2022 - nature.com
Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …

BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection

Y Cao, A Yisimayi, F Jian, W Song, T **ao, L Wang… - Nature, 2022 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage. The receptor …

[HTML][HTML] Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Q Wang, S Iketani, Z Li, L Liu, Y Guo, Y Huang… - Cell, 2023 - cell.com
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …

Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5

Q Wang, Y Guo, S Iketani, MS Nair, Z Li, H Mohri… - Nature, 2022 - nature.com
Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …

Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution

Y Cao, F Jian, J Wang, Y Yu, W Song, A Yisimayi… - Nature, 2023 - nature.com
Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …

Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1. 529 Omicron

H Shuai, JFW Chan, B Hu, Y Chai, TTT Yuen, F Yin… - Nature, 2022 - nature.com
Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto… - Nature, 2022 - nature.com
The emergence of the Omicron variant of SARS-CoV-2 is an urgent global health concern. In
this study, our statistical modelling suggests that Omicron has spread more rapidly than the …

[HTML][HTML] SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron

A Tarke, CH Coelho, Z Zhang, JM Dan, ED Yu… - Cell, 2022 - cell.com
We address whether T cell responses induced by different vaccine platforms (mRNA-1273,
BNT162b2, Ad26. COV2. S, and NVX-CoV2373) cross-recognize early SARS-CoV-2 …

Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants

EK Accorsi, A Britton, KE Fleming-Dutra, ZR Smith… - Jama, 2022 - jamanetwork.com
Importance Assessing COVID-19 vaccine performance against the rapidly spreading SARS-
CoV-2 Omicron variant is critical to inform public health guidance. Objective To estimate the …